In The News
- September 15, 2023
- July 14, 2023
- December 9, 2022
- June 20, 2023
New Diabetes Technology and Therapeutics Supplement Highlights the Latest CGM Evidence and InsightsLearn More
Prescribing of CGM in clinical practice and payer coverage criteria have expanded considering the wealth of evidence and expert recommendations supporting more widespread use. As the body of evidence continues to grow, a new supplement in Diabetes Technology & Therapeutics offers insights from leading clinicians on the latest findings and practical application of CGM. The...
Latest Expert Interview
Addressing Disparities in Care with Evidence-Based Utilization of Diabetes Technology
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGMWatch Now View All Interviews
June 1, 2023
Despite Medicare making strides toward improving access with expanded coverage criteria in recent years, experts in the field of endocrinology are speaking out on the importance of reaching underserved populations with the “potentially life-changing benefits” of CGM technology. In addition to expanded coverage eligibility, Richard M. Bergenstal, MD, noted that access to CGM must be…
October 3, 2022
Source: Population Health Management Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to…
September 15, 2022
CME INFORMATION Release Date: 9/15/2022 Expiration Date: 9/15/2023 TARGET AUDIENCEThis activity is intended for primary care physicians and internal medicine physicians. LEARNING OBJECTIVESUpon completion of this activity, participants will: Have increased knowledge regarding the Data supporting use of rtCGM in practice Have greater competence related to Implementing practical strategies forusing rtCGM in practice
July 15, 2022
This infographic recaps real-time continuous glucose monitoring (rtCGM) abstracts from the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) – where innovation in diabetes medicines and treatments, cutting-edge technologies, and the latest research is presented. These abstracts are pertinent to managed care and payer decision makers and help characterize the value…
May 19, 2022
The American Diabetes Association (ADA) Standards of Medical Care represent the latest evidence-based recommendations for guiding clinical practice. According to the most recent edition of these guidelines, Level A evidence from the MOBILE study supports the use of real time continuous glucose monitoring (rtCGM) in patients with insulin-treated type 2 diabetes (T2D) regardless of regimen….
March 9, 2022
Source: Center for Health Care Strategies Published: January 2022
February 3, 2022
Payer Insights Infographic
January 4, 2022
October 22, 2021
Managed Care Insights Brief
Value of CGM
more patients using rtCGM achieve HEDIS-compliant HbA1C<8% compared with BGM 1 1. Karter AJ, et al. JAMA. 2021;325:2273-2284. doi: 10.1001/jama.2021.6530.
of patients report modifying lifestyle choices due to rtCGM feedback 2 2. Ehrhardt N, et al. Clin Diabetes. 2020;38:126-131. doi: 10.2337/cd19-0037.
in PMPM savings in T2 diabetes related costs according to claims analyses of rtCGM users
3. Norman GJ, et al. Diabetes Technol Ther.
2022;24:520-524. doi: 10.1089/dia.2021.0525.
4. Isaacson B, et al. J Diabetes Sci Technol.
2022;16:383-389. doi: 10.1177/1932296820955228.
PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP
Clinical Pharmacy Specialist and Remote Monitoring Program Coordinator, Cleveland Clinic Diabetes Center